data + articles · 4 listed
newest 2006spec sheet11 rows
Anandamide, also known as N-arachidonoylethanolamine, is a naturally occurring fatty-acid neurotransmitter and the first endocannabinoid to be identified. Discovered in 1992, it is produced on demand in the body from membrane lipids and binds the same cannabinoid receptors targeted by compounds in cannabis. It takes part in the regulation of mood, appetite, memory, pain, and fertility, and is broken down rapidly by the enzyme fatty acid amide hydrolase.
- Mood and sense of wellbeing
- Pain modulation
- Appetite regulation
- Involved in runner's high
Overview
Anandamide (N-arachidonoylethanolamine, often abbreviated AEA) is an endogenous cannabinoid, or endocannabinoid: a signaling molecule built from a fatty acid that acts on the body's cannabinoid receptors. Its name combines the Sanskrit word ananda, meaning bliss or joy, with the chemical term amide. It belongs to a family of lipid messengers called N-acylethanolamines.
Anandamide was isolated from pig brain in 1992 by a team led by Raphael Mechoulam, working with William Devane and Lumir Hanus, during a search for the natural ligand of the recently characterized cannabinoid receptor [1]. Its identification was a landmark because it showed that the brain makes its own cannabis-like compounds, opening up study of what became known as the endocannabinoid system [2].
Rather than being stored, anandamide is synthesized on demand from a membrane phospholipid precursor and released to act near where it is made. It is then taken back up into cells and rapidly hydrolyzed, chiefly by the enzyme fatty acid amide hydrolase (FAAH), into arachidonic acid and ethanolamine. Because FAAH controls how long anandamide persists, inhibitors of this enzyme have been explored as a way to raise natural endocannabinoid tone for therapeutic purposes [2].
Anandamide participates in a wide range of physiological processes, including mood and the response to stress, appetite and energy balance, pain signaling, memory, and early events in pregnancy such as embryo implantation [2]. Dietary intake of the fatty-acid building blocks of endocannabinoids can influence their levels in the brain, as shown in feeding studies in young animals [3]. The system is an active target of drug research in areas ranging from anxiety and pain to metabolic disease.
Anandamide itself is an endogenous substance rather than a manufactured drug product; it is not marketed as a dietary supplement, largely because it is chemically unstable and quickly degraded in the body. Research interest centers less on giving anandamide directly than on modulating the enzymes and receptors that govern its activity.
Mechanism
Anandamide acts mainly as a partial at the cannabinoid receptors CB1 and CB2. CB1 receptors are concentrated in the central nervous system, where anandamide typically works as a retrograde messenger: it is released from a receiving neuron and travels backward across the to quiet the neuron that is sending signals, thereby fine-tuning the release of neurotransmitters such as and [1][2]. CB2 receptors are found more on immune cells and in peripheral tissues.
Anandamide also activates the TRPV1 vanilloid receptor, a channel involved in pain and temperature sensing, giving it effects that reach beyond the classical cannabinoid receptors [2]. Its actions are normally brief because FAAH degrades it quickly; notably, a of the pain reliever acetaminophen, called AM404, interferes with anandamide breakdown and uptake and stimulates TRPV1, which is thought to contribute to that drug's analgesic effect [4].
receptor fingerprint
FAAH enzymesubstrate
CB1 receptorpartial agonist
TRPV1 channelactivates
CB2 receptorpartial agonist
reward pathwaymodulates
Safetyrisks and cautions, not medical advice
As an endogenous molecule it isn't typically sold or taken directly, so human supplement safety data is essentially nonexistent. Approaches that raise anandamide, like FAAH inhibition, carry their own risks; one experimental FAAH inhibitor caused a serious clinical trial accident. Cannabinoid-system modulation can affect mood, cognition, and heart rate.
Subjective profileweighing the evidence above
Important endogenous molecule, but not something you meaningfully supplement directly. The interesting lever is slowing its breakdown, not swallowing it.
Resources
This entry is here for reference.
Research
- 1992first citedIsolation and structure of a brain constituent that binds to the cannabinoid receptor
- 2006most recentThe endocannabinoid system as an emerging target of pharmacotherapy
- 1.Isolation and structure of a brain constituent that binds to the cannabinoid receptor
- 2.The endocannabinoid system as an emerging target of pharmacotherapy
- 3.Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets.
- 4.Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system.
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Can I just take anandamide as a pill?
Not effectively. Your body breaks it down almost instantly with the FAAH enzyme, so oral anandamide has little practical effect.
What raises anandamide naturally?
Exercise, especially sustained aerobic effort, raises anandamide and is part of the runner's high. FAAH inhibition also raises it, but that's experimental.
Is anandamide like THC?
It acts on the same CB1 receptors THC does, but it's a partial agonist and is regulated tightly by the body, so the effect is subtler and short-lived.
What's a practical alternative?
PEA (palmitoylethanolamide) is a related fatty acid amide that's actually sold as a supplement and may support endocannabinoid tone.
Notes and cautions
- Not sold or taken as a supplement
- Made and broken down within the body
- Too unstable to use directly as a drug
- Research focuses on the enzymes and receptors that control it